ZAP 2 trial - A randomised trial of zoledronic acid for osteoarthritis of the knee
The ZAP 2 trial is a multicentre randomised controlled trial examining a new treatment for knee osteoarthritis. It is supported by the National Health and Medical Research Council (NHMRC ID 1045415).
The aim of this study is to compare, using a randomised, placebo-controlled double-blind design over two years, the effect of an annual infusion of zoledronic acid to placebo on knee structural change assessed on magnetic resonance imaging (MRI) and knee pain.
Patients have been recruited from Hobart, Melbourne, Sydney and Adelaide. Eligible subjects will receive an annual identical intravenous infusion of zoledronic acid (5mg in normal saline) or placebo (normal saline), over two years. Outcome measures include cartilage loss over 24 months, knee pain at 3, 6,12, 18, and 24 months, and bone marrow lesion size over 6 and 24 months.Recruitment for this study is now complete. Please contact Kathy.Buttigieg@utas.edu.au (03 6226 6909) (Mon, Tues & Fri) for more information.
- Dr Dawn Aitken
- Dr Laura Laslett
- Professor Changhai Ding
- Associate Professor Leigh Blizzard
- Sarah Day
- Kathy Buttigieg
- Professor Flavia Cicuttini - Monash University
- Associate Professor Lyn March - Sydney University
- Associate Professor Catherine Hill - Queen Elizabeth Hospital, Adelaide